NGM
Price:
$1.54
Market Cap:
$128.53M
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is...[Read more]
Industry
Biotechnology
IPO Date
2019-04-04
Stock Exchange
NASDAQ
Ticker
NGM
According to NGM Biopharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.79. This represents a change of 6.34% compared to the average of 7.33 of the last 4 quarters.
The mean historical Current Ratio of NGM Biopharmaceuticals, Inc. over the last ten years is 6.54. The current 7.79 Current Ratio has changed 11.80% with respect to the historical average. Over the past ten years (40 quarters), NGM's Current Ratio was at its highest in in the March 2020 quarter at 11.89. The Current Ratio was at its lowest in in the March 2018 quarter at 0.
Average
6.54
Median
6.20
Minimum
4.76
Maximum
8.94
Discovering the peaks and valleys of NGM Biopharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 72.94%
Maximum Annual Current Ratio = 8.94
Minimum Annual Increase = -23.58%
Minimum Annual Current Ratio = 4.76
Year | Current Ratio | Change |
---|---|---|
2023 | 7.79 | 29.03% |
2022 | 6.04 | -2.33% |
2021 | 6.18 | -14.65% |
2020 | 7.24 | -19.02% |
2019 | 8.94 | 72.94% |
2018 | 5.17 | 8.70% |
2017 | 4.76 | -23.58% |
The current Current Ratio of NGM Biopharmaceuticals, Inc. (NGM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.67
5-year avg
7.24
10-year avg
6.54
NGM Biopharmaceuticals, Inc.’s Current Ratio is less than Neoleukin Therapeutics, Inc. (15.33), less than Instil Bio, Inc. (15.06), less than Achilles Therapeutics plc (8.24), less than NextCure, Inc. (8.35), greater than Assembly Biosciences, Inc. (2.74), less than Erasca, Inc. (16.79), less than Century Therapeutics, Inc. (10.62), less than Keros Therapeutics, Inc. (20.37), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Nkarta, Inc. (15.91), less than Lyell Immunopharma, Inc. (16.19), greater than Generation Bio Co. (7.42), greater than Sana Biotechnology, Inc. (5.20), less than Kezar Life Sciences, Inc. (9.58), less than Mineralys Therapeutics, Inc. (11.20), greater than Foghorn Therapeutics Inc. (5.69), greater than C4 Therapeutics, Inc. (5.09), less than Cyteir Therapeutics, Inc. (21.89), less than Prelude Therapeutics Incorporated (7.83), less than Rezolute, Inc. (11.82),
Company | Current Ratio | Market cap |
---|---|---|
15.33 | $8.20M | |
15.06 | $92.68M | |
8.24 | $29.58M | |
8.35 | $39.73M | |
2.74 | $107.81M | |
16.79 | $807.96M | |
10.62 | $123.69M | |
20.37 | $1.97B | |
6.56 | $349.21M | |
15.91 | $375.37M | |
16.19 | $299.52M | |
7.42 | $145.50M | |
5.20 | $1.12B | |
9.58 | $40.82M | |
11.20 | $558.43M | |
5.69 | $416.63M | |
5.09 | $374.42M | |
21.89 | $108.71M | |
7.83 | $266.87M | |
11.82 | $240.80M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NGM Biopharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NGM Biopharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is NGM Biopharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for NGM Biopharmaceuticals, Inc. (NGM)?
What is the highest Current Ratio for NGM Biopharmaceuticals, Inc. (NGM)?
What is the 3-year average Current Ratio for NGM Biopharmaceuticals, Inc. (NGM)?
What is the 5-year average Current Ratio for NGM Biopharmaceuticals, Inc. (NGM)?
How does the current Current Ratio for NGM Biopharmaceuticals, Inc. (NGM) compare to its historical average?